Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2023 Dec 7;14:1349235. doi: 10.3389/fphar.2023.1349235

Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin

Frontiers Editorial Office*
PMCID: PMC10733853  PMID: 38130404

The journal retracts the 29 January 2020 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES